Company Filing History:
Years Active: 1998-1999
Title: Innovator in Oncology: The Contributions of Makoto Makishima
Introduction: Makoto Makishima is a distinguished inventor based in Saitama-ken, Japan, recognized for his significant contributions to the field of oncology. With two patents to his name, his work primarily focuses on pharmaceutical compositions aimed at treating leukemia. His innovative approaches have the potential to enhance treatment outcomes for patients battling this serious illness.
Latest Patents: Makoto Makishima holds two notable patents that highlight the therapeutic efficacy of his inventions. The first patent is for a pharmaceutical composition for the treatment of leukemia containing 9-Cis-retinoic acid and alpha-tocopherol esters. This formulation is designed to promote remission in leukemia patients. Furthermore, his research elucidates that the combined use of 9-Cis-retinoic acid and either 1-alpha,25-dihydroxyvitamin D3 or additional 9-Cis-retinoic acid can provide a synergistic effect, offering treatment advantages without the side effects commonly attributed to traditional therapies.
Career Highlights: Makoto Makishima is associated with Nisshin Flour Milling Co., Ltd., where he has applied his expertise in pharmaceutical innovation. His dedicated research in pharmaceutical sciences has positioned him as a key figure in advancing leukemia treatments through his inventive methodologies.
Collaborations: Throughout his career, Makoto has collaborated with esteemed colleagues, including Yasuhiro Kanatani and Yoshio Honma. These partnerships have fostered a collaborative environment that promotes shared knowledge and expertise in their mutual goal of enhancing therapeutic strategies for leukemia.
Conclusion: Makoto Makishima’s contributions to the field of pharmaceuticals, particularly in leukemia treatment, underpin his status as a valuable inventor. His patents reflect a commitment to innovative healthcare solutions that may significantly improve patient outcomes. As he continues to work with his colleagues, the advancements stemming from his research are likely to play a crucial role in future therapeutic applications.